Literature DB >> 19375851

Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis.

Sharad S Singhal1, Sushma Yadav, Rit Vatsyayan, Pankaj Chaudhary, Jozef Borvak, Jyotsana Singhal, Sanjay Awasthi.   

Abstract

RLIP76 is a stress-responsive <span class="Chemical">glutathione-electrophile-conjugates (GS-E) and drugs transporter which is over-expressed in different types of cancers. Cdc2 is a cell-cycle check point control kinase which has been shown to bind to RLIP76 during mitosis, such that endocytosis is inhibited. In present studies, we have purified cdc2 and examined its effect on the transport activity of RLIP76 reconstituted into artificial liposomes. Both doxorubicin (DOX) and dinitro-phenyl S-glutathione (DNP-SG) transport were inhibited by cdc2 in a concentration dependent manner. Liposomal delivery of cdc2 to H358 cells caused apoptosis, resulted in an increased intracellular doxorubicin-accumulation and decreased rate of efflux from the cells. In the present communication, we propose that the accumulation-deficient drug-resistance mediated by RLIP76 can be modulated by inhibition of RLIP76 transport activity by cdc2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375851      PMCID: PMC2721022          DOI: 10.1016/j.canlet.2009.03.033

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle.

Authors:  Roy M Golsteyn
Journal:  Cancer Lett       Date:  2005-01-20       Impact factor: 8.679

2.  HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo.

Authors:  Yanzhong Hu; Nahid F Mivechi
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

3.  A putative effector of Ral has homology to Rho/Rac GTPase activating proteins.

Authors:  S H Park; R A Weinberg
Journal:  Oncogene       Date:  1995-12-07       Impact factor: 9.867

4.  Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis.

Authors:  K Morinaka; S Koyama; S Nakashima; T Hinoi; K Okawa; A Iwamatsu; A Kikuchi
Journal:  Oncogene       Date:  1999-10-21       Impact factor: 9.867

5.  Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress.

Authors:  J Z Cheng; R Sharma; Y Yang; S S Singhal; A Sharma; M K Saini; S V Singh; P Zimniak; S Awasthi; Y C Awasthi
Journal:  J Biol Chem       Date:  2001-08-24       Impact factor: 5.157

6.  Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin.

Authors:  S Awasthi; J Cheng; S S Singhal; M K Saini; U Pandya; S Pikula; J Bandorowicz-Pikula; S V Singh; P Zimniak; Y C Awasthi
Journal:  Biochemistry       Date:  2000-08-08       Impact factor: 3.162

7.  Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1.

Authors:  Sharad S Singhal; Sushma Yadav; Kenneth Drake; Jyotsana Singhal; Sanjay Awasthi
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

8.  Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity.

Authors:  Sanjay Awasthi; Sharad S Singhal; Jyotsana Singhal; Yusong Yang; Piotr Zimniak; Yogesh C Awasthi
Journal:  Int J Oncol       Date:  2003-04       Impact factor: 5.650

9.  Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity.

Authors:  V Jullien-Flores; O Dorseuil; F Romero; F Letourneur; S Saragosti; R Berger; A Tavitian; G Gacon; J H Camonis
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

10.  Cytocentrin is a Ral-binding protein involved in the assembly and function of the mitotic apparatus.

Authors:  A Quaroni; E C Paul
Journal:  J Cell Sci       Date:  1999-03       Impact factor: 5.285

View more
  12 in total

1.  Targeting p53-null neuroblastomas through RLIP76.

Authors:  Jyotsana Singhal; Sushma Yadav; Lokesh Dalasanur Nagaprashantha; Rit Vatsyayan; Sharad S Singhal; Sanjay Awasthi
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-16

2.  Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.

Authors:  Qi Wang; Jun Qian; Junyu Wang; Chun Luo; Juxiang Chen; Guohan Hu; Yicheng Lu
Journal:  J Neurooncol       Date:  2013-01-06       Impact factor: 4.130

3.  Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer.

Authors:  Lokesh Dalasanur Nagaprashantha; Rit Vatsyayan; Jyotsana Singhal; Spence Fast; Rhonda Roby; Sanjay Awasthi; Sharad S Singhal
Journal:  Biochem Pharmacol       Date:  2011-07-23       Impact factor: 5.858

4.  Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.

Authors:  Baosheng Zhou; Guoyun Bu; Yipin Zhou; Yue Zhao; Wei Li; Mu Li
Journal:  Med Oncol       Date:  2014-11-30       Impact factor: 3.064

5.  Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma.

Authors:  Tingting Wang; Yuhua Jiang; Lei Chu; Tianhui Wu; Jie You
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

6.  Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse.

Authors:  Nathan M Mollberg; Gunnar Steinert; Maximillian Aigner; Alexander Hamm; Fang-Ju Lin; Heike Elbers; Christoph Reissfelder; Jürgen Weitz; Markus W Buchler; Moritz Koch
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

Review 7.  RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.

Authors:  Sharad S Singhal; Lokesh Nagaprashantha; Preeti Singhal; Sulabh Singhal; Jyotsana Singhal; Sanjay Awasthi; David Horne
Journal:  Pharm Res       Date:  2017-04-06       Impact factor: 4.200

Review 8.  RLIP76: a versatile transporter and an emerging target for cancer therapy.

Authors:  Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sanjay Awasthi; Sharad S Singhal
Journal:  Biochem Pharmacol       Date:  2010-01-25       Impact factor: 5.858

9.  Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells.

Authors:  Kun Yao; Hongchang Xing; Wei Yang; Aijun Liao; Bin Wu; Yingchun Li; Rong Zhang; Zhuogang Liu
Journal:  Tumour Biol       Date:  2014-05-18

10.  RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.

Authors:  Jyotsana Singhal; Lokesh Nagaprashantha; Rit Vatsyayan; Sanjay Awasthi; Sharad S Singhal
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.